← Leaderboards
Michael Pawlita
$19,536,054
Attributed
$19,536,054
Total exposure
14
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$19,536,054 · 14
By mechanism
N03$17,434,785 · 11
N01$1,851,671 · 4
N02$249,598 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsNational Cancer InstituteUnited StatesProgramsCancer PatientReportingCancer TherapyDiagnosisDivision Of Cancer Control And Population SciencesMonitorIncidenceTrendPatterns Of CarePatternCancer ControlCancer Control Research ProgramResourcesBaseResponseBiological MarkersStagingFemaleCost EffectiveChemotherapy
Grant awards (27)
Surveillance, Epidemiology, and End Results (SEER) Program$3,630,335
N03 · FY2013 · CA · contact PI
Surveillance, Epidemiology, and End Results (SEER) Program$3,015,029
N03 · FY2013 · CA · contact PI
Surveillance, Epidemiology, and End Results (SEER) Program$2,550,457
N03 · FY2013 · CA · contact PI
Surveillance, Epidemiology, and End Results (SEER) Program$2,395,196
N03 · FY2013 · CA · contact PI
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS (SEER) PROGRAM$1,983,049
N03 · FY2013 · CA · contact PI
Surveillance, Epidemiology, and End Results (SEER) Program$1,028,057
N03 · FY2013 · CA · contact PI
MUC1 Vaccine in Patients with Newly Diagnosed Advanced Adenomas$939,452
N03 · FY2013 · CA · contact PI
Chemoprevention of Prostate Cancer via Estrogen Receptor B Agonists$686,259
N01 · FY2013 · CA · contact PI
Evaluation of iNOS Antagonists in the Prevention of Oral Cancer - HHSN261201200$621,261
N03 · FY2013 · CA · contact PI
Effects Of Chemopreventive Agents On Biomarkers Related To Lung Tumorigenesis: Al$615,035
N01 · FY2013 · CA · contact PI
Core Infrastructure Support$612,086
N03 · FY2013 · CA · contact PI
Efficacy of Eldecalcitol (ED-71) in Colorectal Cancer$303,650
N01 · FY2013 · CA · contact PI
DCCPS Communications$187,034
N03 · FY2013 · CA · contact PI
Preclinical Pharmacology and Toxicology Studies$165,842
N01 · FY2013 · CA · contact PI
Patterns of Care/Quality of Care - Diagnosis Year 2012$149,693
N03 · FY2013 · CA · contact PI
Meeting Support for Applied Research Program$134,889
N02 · FY2013 · CA · contact PI
Patterns of Care/Quality of Care Study - Diagnosis Year 2012; HHSN261201300004I T$128,934
N03 · FY2013 · CA · contact PI
Meeting Support for Applied Research Program$90,000
N02 · FY2013 · CA · contact PI
Patterns of Care/Quality of Care - Diagnosis Year 2012$80,885
N01 · FY2013 · CA · contact PI
Patterns of Care/Quality of Care Study - Diagnosis Year 2012; HHSN261201300019I -$39,898
N03 · FY2013 · CA · contact PI
Patterns of Care/Quality of Care Study - Diagnosis Year 2012; HHSN261201300009I T$39,102
N03 · FY2013 · CA · contact PI
Epidemiology Genetics Research Program Meeting Support & Technical Support.$38,256
N03 · FY2013 · OD · contact PI
Annual Pain Consortium Symposium$36,087
N03 · FY2013 · NS · contact PI
Meeting Support for Applied Research Program$24,709
N02 · FY2013 · CA · contact PI
Patterns of Care/Quality of Care Study - Diagnosis Year 2012; HHSN261201300010I T$22,346
N03 · FY2013 · CA · contact PI
Annual Pain Consortium Symposium$13,913
N03 · FY2013 · NS · contact PI
Program Evaluaton, Planning and Coordination Services$4,600
N03 · FY2013 · CA · contact PI